 |
市場調查報告書
商品編碼
1268027
肥胖 - 管道分析：2023 年Obesity-Pipeline Analytics -2023 |
||||||
價格
簡介目錄
肥胖是一個公共衛生問題，其患病率在全球範圍內不斷上升。 它現在如此流行，以至於被美國醫學協會 (2013) 和歐盟委員會 (2021) 列為慢性病。 肥胖對生活質量有重大影響，導致醫療保健成本增加，肥胖者會產生多種健康風險，包括心血管疾病、2 型糖尿病、某些癌症和肌肉骨骼疾病。據說會增加患以下疾病的風險
本報告探討了肥胖症，並按階段概述了肥胖症、管道趨勢、競爭格局和管道藥物。
內容
概覽
肥胖目標
- 介紹
- 流行病學和病因學
- 肥胖的病理生理學
- 肥胖的發病機制
- 胰高血糖素樣□-1 (GLP-1) 在肥胖症中的作用
- 2022 年肥胖治療指南
- 為患者選擇最合適的減肥藥提供基於證據的建議
- 治療可能導致肥胖的 T2D（2 型糖尿病）的非處方藥
肥胖管道分析，按階段
- 肥胖 - III 期和 II 期管道分析摘要
- 按開發階段劃分的管道產品
- 肥胖症競爭格局，按階段、按路線
- 臨床管線（3 期-1 期）產品，按公司分類
- 肥胖症單一療法和聯合療法的臨床試驗
- 按作用機制分類的在研產品
- 早期和臨床階段的新機制
- 肥胖臨床和監管時間表
- 後期概況比較概覽
肥胖許可、收購和合作
肥胖管道景觀
- 肥胖症臨床管線狀態
第三階段
- Kagrisema（諾和諾德 A/S）
- DOR/3TC/TDF（默克公司）
- Tilzepatide（禮來公司）
- IBI362（信達生物製品（蘇州）有限公司）
肥胖管道景觀
第二階段
- DCCR（Soleno Therapeutics, Inc.）
- MBL949（諾華）
- BI 456906（Zealand Pharma/Boehringer Ingelheim）
- LY3502970（禮來公司）
- XW-003（Sciwind Biosciences）
- ARD-101（土豚療法）
- 達努列酮（輝瑞）
- PF-07081532 (Sosei Heptares)
- Pembidutide（Altimmune, Inc.）
- Retatortide（禮來公司）
- TG103（Genexine/天境生物/石藥集團）
- APHD-012（Aphaia 製藥公司）
- Bimagrumab（Versanis Bio, Inc./Novartis）
- HSG4112 (Glaceum)
- SHR20004（江蘇恆瑞醫藥有限公司）
- AMG-133（安進）
- 1875 年（諾和諾德公司）
- 卡格列□（Novo Nordisk A/S）
- EMP-16-02（Empros 製藥公司）
第I階段
- EMP-16-02（Empros Pharma）
- AMG-786（Amgen）
- BMS-963272（Bristol-Myers Squibb）
- DD01（D&D Pharmatech）
- ERX1000（ERX Pharmaceuticals）
- GMA106（Gmax Biopharm）
- LY3457263（Eli Lilly and Company）
- NNC0247-0829（Novo Nordisk）
- 阿米克汀（Novo Nordisk）
- NO-13065（Otsuka Pharmaceutical Factory, Inc）
- S-309309（Shionogi）
- HM15136（Hanmi Pharmaceutical Company Limited）
- DR10624（Zhejiang Doer Biologics）
- LY3841136（Eli Lilly and Company）
- DACRA QW II（Eli Lilly and Company）
- AZD6234（AstraZeneca）
- CT-388（Carmot Therapeutics, Inc）
- INV-202（Inversago Pharma Inc.）
- BI 1820237（Boehringer Ingelheim）
- ZP 8396（Zealand Pharma）
- MVD1（Eolo pharma）
- VK2735（Viking Therapeutics）
- GSBR-1290（Structure Therapeutics）
- XW014（Sciwind Biosciences）
- CIN-109（CinFina Pharma）
- CB4211（CohBar）
- DWP306001（Daewoong Pharmaceutical）
- LR19021（LG Life Sciences）
- ECC5004（Eccogene）
- SCO267（SCOHIA PHARMA, Inc）
- SCO094（SCOHIA PHARMA, Inc./Huadong Medicine）
- BC LisPram（Adocia）
- GUB002496（Gubra Therapeutics/Boehringer Ingelheim）
- MT961（Medytox）
肥胖臨床前管線景觀
肥胖的SWOT分析
附錄
簡介目錄
Product Code: MM1114734
Obesity report provides a comprehensive analysis of the obesity market, with an in-depth analysis of key pipeline products, licensing, acquisition, and collaboration deals. The report covers around 120+ products with 50 companies and their 65 products is clinical stages, providing valuable insights to companies seeking to expand their research in this therapy area. In addition, our report provides in-depth profiles of obesity candidates, including preclinical and clinical studies, details of partnerships and business deal values, targeted technologies, investments, and acquisition trends. We also provide licensing opportunities, acquisition trends, and product analysis by phases, company & MOA. Furthermore, the report covers descriptive information on the competitive pipeline landscape.
Obesity is a growing public health concern, with increasing prevalence worldwide. It has become so prevalent that it is now classified by the American Medical Association (2013) and the European Commission (2021) as a chronic disease. Obesity has a significant impact on quality of life and results in increased healthcare costs, with individuals with obesity at increased risk of developing numerous health risks, including cardiovascular disease, type 2 diabetes, certain cancers, and musculoskeletal disorders.
In this report, Mellalta Meets provides an in-depth analysis of Obesity pipeline covering Phase III & Phase II Pipeline Analysis Overview, Pipeline Products by Stage of Development, Obesity Competitive Landscape Distinguished by Phase & Route, Clinical Pipeline Products by Company, Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Novel Mechanisms in Early and Clinical Stages , Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are more than 65 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are Novo Nordisk, Merck & Co, Eli Lilly and Company, and Innovent Biologics (Suzhou) Co. Ltd and many more which have robust clinical pipelines of OBESITY inhibitor candidates. As per analysis, despite the challenges in the pipeline development of obesity, the obesity market looks set to become the next blockbuster pharma category.
Key Highlights of Obesity Report:
- The Obesity segment is dominated by the pre-clinical assets (XX) which represent XX% of the total development followed by Phase 1 assets (XX) representing XX%, Phase 2 assets (XX) with XX%, discovery (XX) with 13% and Phase 3 (4) representing 3% of the pipeline development in Obesity.
- The obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage obesity therapies, followed by China and Denmark with XX%. With Eli Lilly leading the pack in product development, closely trailed by Novo Nordisk and Zealand Pharma, the obesity pipeline showcases a robust and diverse range of innovative solutions to address the global obesity epidemic. These industry giants are set to transform the landscape with ground-breaking treatments, tapping into new mechanisms of action and combination therapies for enhanced efficacy and improved patient adherence.
- Obesity pipeline landscape includes 85% of Monotherapy trials, 3% combination therapy and 12% of Combination/monotherapy trials.
- The Obesity segment is dominated by the pre-clinical assets (46), phase 1 assets (37), phase 2 assets (24) and phase 3 (4).
Report Coverage:
- Indication Prioritisation: Obesity market potential based on Indications.
- Business Transactions & Strategies: Key collaborations and deal values
- Obesity Pipeline Development: Product Profiles, Clinical Trials & Results
- Obesity Acquisition Targets
- Obesity Competitive Intelligence
- Recent & Upcoming events
TABLE OF CONTENTS
OVERVIEW
The Obesity Target BACKGROUND
- Introduction
- Epidemiology & Causes
- Pathophysiology of Obesity
- Obesity pathomechanisms
- Role of Glucagon-like peptide-1 (GLP-1) in obesity
- 2022 Obesity Treatment Guidelines
- Evidence-based recommendations for selecting the most appropriate weight loss medications for their patients
- Marketed Drugs in T2D (Type 2 diabetes) with potential outcomes in Obesity
Obesity PIPELINE ANALYSIS by Phases
- Obesity - Phase III & Phase II Pipeline Analysis Overview
- Pipeline Products by Stage of Development
- Obesity Competitive Landscape Distinguished by Phase & Route
- Clinical Pipeline (Phase 3 - Phase 1) Products by Company
- Obesity Monotherapy & Combinations Clinical Trials
- Pipeline Products by MOA
- Novel Mechanisms in Early and Clinical Stages
- Obesity Clinical & Regulatory Timelines
- Late-Stage Profiles Comparisons At-a-glance
Obesity Licensing, Acquisition And Collaboration
- Obesity Licensing, Acquisition, and Deal values
- Obesity Licensing by Transaction type and total amount size by Phases
Obesity Pipeline Landscape
- Obesity Clinical Pipeline Landscape
Phase III
- CagriSema (Novo Nordisk A/S)
- Product Profile
- Clinical Trials
- Collaborations
- Other Developments
- DOR/3TC/TDF (Merck & Co)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Tirzepatide (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- IBI362 (Innovent Biologics (Suzhou) Co. Ltd.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
Obesity Pipeline Landscape
Phase II
- DCCR (Soleno Therapeutics, Inc.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- MBL949 (Novartis)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- BI 456906 (Zealand Pharma/Boehringer Ingelheim)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- LY3502970 (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- XW-003 (Sciwind Biosciences)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- ARD-101 (Aardvark Therapeutics)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Danuglipron (Pfizer)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- PF-07081532 (Sosei Heptares)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Pemvidutide (Altimmune, Inc.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Retatrutide (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- TG103 (Genexine/I-Mab Biopharma/CSPC Pharmaceutical)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- APHD-012 (Aphaia Pharma)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Bimagrumab (Versanis Bio, Inc./ Novartis)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- HSG4112 (Glaceum)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- SHR20004 (Jiangsu HengRui Medicine Co.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- AMG-133 (Amgen)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- PYY 1875 (Novo Nordisk A/S)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Cagrilintide (Novo Nordisk A/S)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- EMP-16-02 (Empros Pharma)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
Phase I
- EMP-16-02 (Empros Pharma)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- AMG-786 (Amgen)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- BMS-963272 (Bristol-Myers Squibb)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- DD01 (D&D Pharmatech)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- ERX1000 (ERX Pharmaceuticals)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- GMA106 (Gmax Biopharm)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- LY3457263 (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- NNC0247-0829 (Novo Nordisk)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- Amycretin (Novo Nordisk)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- NO-13065 (Otsuka Pharmaceutical Factory, Inc.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- S-309309 (Shionogi)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- HM15136 (Hanmi Pharmaceutical Company Limited)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- DR10624 (Zhejiang Doer Biologics)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- LY3841136 (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- DACRA QW II (Eli Lilly and Company)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- AZD6234 (AstraZeneca)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- CT-388 (Carmot Therapeutics, Inc.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- INV-202 (Inversago Pharma Inc.)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- BI 1820237 (Boehringer Ingelheim)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- ZP 8396 (Zealand Pharma)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- MVD1 (Eolo pharma)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- VK2735 (Viking Therapeutics)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- GSBR-1290 (Structure Therapeutics)
- Product Profile & Description
- Clinical Trials
- Collaborations
- Other Developments
- XW014 (Sciwind Biosciences)
- Product Profile & Description
- Collaborations
- Other Developments
- CIN-109 (CinFina Pharma)
- Product Profile & Description
- Collaborations
- Other Developments
- CB4211 (CohBar)
- Product Profile & Description
- Collaborations
- Other Developments
- DWP306001 (Daewoong Pharmaceutical)
- Product Profile & Description
- Collaborations
- Other Developments
- LR19021 (LG Life Sciences)
- Product Profile & Description
- Collaborations
- Other Developments
- ECC5004 (Eccogene)
- Product Profile & Description
- Collaborations
- Other Developments
- SCO267 (SCOHIA PHARMA, Inc.)
- Product Profile & Description
- Collaborations
- Other Developments
- SCO094 (SCOHIA PHARMA, Inc./Huadong Medicine)
- Product Profile & Description
- Collaborations
- Other Developments
- BC LisPram (Adocia)
- Product Profile & Description
- Collaborations
- Other Developments
- GUB002496 (Gubra Therapeutics/Boehringer Ingelheim)
- Product Profile & Description
- Collaborations
- Other Developments
- MT961 (Medytox)
- Product Profile & Description
- Collaborations
- Other Developments
Obesity Pre-clinical Pipeline Landscape
Obesity SWOT Analysis
Appendix
- About us
02-2729-4219
+886-2-2729-4219
抗肥胖藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按機制（周邊作用藥物、中樞作用藥物）、藥物類型（處方藥、非處方藥）、地區和競爭細分，2019- 2029F
抗肥胖藥物市場：依藥物類型、作用機轉分類 - 全球預測 2025-2030
抗肥胖處方藥市場：按藥物類別、年齡層、分銷管道分類 - 全球預測 2025-2030
肥胖治療市場：按藥物、手術、設備分類 - 全球預測 2025-2030
肥胖藥物市場：依治療類型、最終用途分類 - 2025-2030 年全球預測
男性女乳症手術市場 - 全球產業規模、佔有率、趨勢、機會和預測，按年齡層、手術類型、最終用途、地區和競爭細分，2019-2029F
2024-2032年按藥物類別（周邊作用藥物、中樞作用藥物）、藥物類型（處方藥、非處方藥）、配銷通路（醫院藥房、零售藥房、線上藥房）和地區分類的抗肥胖藥物市場報告
抗肥胖藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032
抗肥胖藥物市場：2024-2034
抗肥胖藥物市場、佔有率、規模、趨勢、產業分析報告：依作用機制、依產品、依分銷管道、依地區、依細分市場預測，2024-2032
▼